OncoMatch/Clinical Trials/NCT07167160
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Is NCT07167160 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Camrelizumab combined with chemotherapy for cervical cancer.
Treatment: Camrelizumab combined with chemotherapy — Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) positive expression (positive)
Disease stage
Required: Stage FIGO2018 IIIC1P, FIGO2018 IIIC2P (FIGO2018)
staged FIGO2018 IIIC1p or IIIC2p after radical surgery
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: radical surgery
after radical surgery
Cannot have received: immune checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07167160 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 positive expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO2018 IIIC1P or FIGO2018 IIIC2P is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages